Methods of reducing extravasation of inflammatory cells

Details Methods of reducing extravasation of inflammatory cells Methods of reducing extravasation of inflammatory cells

2011-06-14

2011-06-14

Kim, Taeyoon (Department: 1651)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C424S094500, C424S094100, C435S232000

Reexamination Certificate

active

07959914

ABSTRACT:
A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.

REFERENCES:
patent: 5262522 (1993-11-01), Gearing
patent: 5496718 (1996-03-01), Hashimoto
patent: 5498536 (1996-03-01), Khandke
patent: 5578480 (1996-11-01), Khandke
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5763205 (1998-06-01), Hashimoto et al.
patent: 5792743 (1998-08-01), Schachner
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5869301 (1999-02-01), Nghiem et al.
patent: 5997863 (1999-12-01), Zimmermann et al.
patent: 6007810 (1999-12-01), Ishikawa et al.
patent: 6063378 (2000-05-01), Nohara et al.
patent: 6093563 (2000-07-01), Bennett et al.
patent: 6153187 (2000-11-01), Yacoby-Zeevi
patent: 6171575 (2001-01-01), Okuyama
patent: 6200564 (2001-03-01), Lamont et al.
patent: 6248562 (2001-06-01), Dunn et al.
patent: 6313265 (2001-11-01), Phillips et al.
patent: 6326166 (2001-12-01), Pomerantz et al.
patent: 6972168 (2005-12-01), Muir
patent: 7008783 (2006-03-01), Sato et al.
patent: 7163545 (2007-01-01), Yaszemski et al.
patent: 7465705 (2008-12-01), Lee et al.
patent: 2003/0040112 (2003-02-01), Muir et al.
patent: 2003/0072749 (2003-04-01), Muir et al.
patent: 2003/0077258 (2003-04-01), Muir
patent: 2004/0033221 (2004-02-01), Masuda et al.
patent: 2004/0265297 (2004-12-01), Gruskin et al.
patent: 2005/0118157 (2005-06-01), McMahon et al.
patent: 2005/0233419 (2005-10-01), Pojasek et al.
patent: 2006/0078959 (2006-04-01), Prabhakar et al.
patent: 2006/0153827 (2006-07-01), Gruskin et al.
patent: 2006/0233782 (2006-10-01), Gruskin et al.
patent: 2007/0104703 (2007-05-01), Caggiano et al.
patent: 2007/0274979 (2007-11-01), Gruskin et al.
patent: 2003/208466 (2003-09-01), None
patent: 2004241088 (2004-12-01), None
patent: 0704532 (1996-03-01), None
patent: 1646353 (2006-04-01), None
patent: WO 91/06303 (1991-05-01), None
patent: WO 94/25567 (1994-11-01), None
patent: WO 95/13091 (1995-05-01), None
patent: WO 99/46368 (1999-09-01), None
patent: WO 00/62067 (2000-10-01), None
patent: WO 00/64482 (2000-11-01), None
patent: WO 01/39795 (2001-06-01), None
patent: WO 02/08285 (2002-01-01), None
patent: WO 02/055684 (2002-07-01), None
patent: WO 02/065136 (2002-08-01), None
patent: WO 02/083179 (2002-10-01), None
patent: WO 03/000901 (2003-01-01), None
patent: WO 03/015612 (2003-02-01), None
patent: WO 03/022882 (2003-03-01), None
patent: WO 03/031578 (2003-04-01), None
patent: WO 03/074080 (2003-09-01), None
patent: WO 03/100031 (2003-12-01), None
patent: WO 03/102160 (2003-12-01), None
patent: WO 2004/017044 (2004-02-01), None
patent: WO 2004/103299 (2004-12-01), None
patent: WO 2004/110359 (2004-12-01), None
patent: WO 2004/110360 (2004-12-01), None
patent: WO 2005/087920 (2005-09-01), None
patent: WO 2005/112986 (2005-12-01), None
patent: WO 2007/038548 (2007-04-01), None
Ratjen et al. 2003. Cystic fibrosis. The Lancet. 361(9358):681-689.
Oermann et al. 1999. The Use of Anti-inflammatory Medications in Cystic Fibrosis. Chest. 115:1053-1058.
DeGrendele et al. 1997. Requirement for CD44 in Activated T Cell Extravasation into an Inflammatory Site. Science. 278:672-675.
Iida et al. 1996. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Seminars in Cancer Biology. vol. 7:155-162.
Lesley et al. 1995. Variant Cell Lines Selected for Alterations in the Function of the Hyaluronan Receptor CD44 Show Differences in Glycosylation. J. Exp. Med. 182:431-437.
Smiseth et al., Effect of Hyaluronidase on Substrate Exchange and Blood Flow in the Ischaemic Myocardium of the Dog, 1982, Clinical Physiology, 2(1):39-50.
Zuo et al, Regeneration of axons after nerve transaction repair is enhanced by degradation of chondroitin sulfate proteoglycan, Exp. Neurol. 176(1):221-228, 2002.
Bradbury et al, Chondroitinase ABC promotes functional recovery after spinal cord injury, Nature 416:636-640, 2002.
Curinga et al., Mammalian-Produced Chondroitinase AC Mitigates Axon Inhibition by Chondroitin Sulfate Proteoglycans, Journal of Neurochemistry, 2007, 102:275-288.
Crespo et al., How does Chondroitinase Functional Recovery in the Damaged CNS?, Experimental Neurology, 2007, 206:159-171.
Accession P59807, Aug. 15, 2003UniProtKB/Swiss-Prot.
Aldrich “Enzymer Explorer” 2009, URL:http://www.sigmaaldrich.com/life-science/metabolomics/enzyme-explorer/learning-center/carbohydrate-analysis/carbohydrate-analysis-iii.
Anderson et al. “Tumor Cell Retention of Antibody Fab Fragments is Enhanced by an Attached HIV TAT Protein-Derived Peptide” 1993,Biochem.&Biophys. Res. Commun.194(2):876-884.
Appel et al. “Several Extracellular Domains of the Neural Cell Adhesion Molecule L1 are Involved in Neurite Outgrowth and Cell Body Adhesion” 1993,J. Neurosc.13(11): 4764-4775.
Avrameas et al. “Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules” 1998,Proc. Natl. Acad. Sci. USA95:5601-5606.
Bao et al. “A Functional Dermatan Sulfate Epitope Containing Iduronate (2-O-sulfate) α1-3GalNAC (6-O-sulfate) Disaccharide in the Mouse Brain” 2005,J. of Bio. Chem.280(24):23184-23193.
Basso et al. “A Sensitive and Reliable Locomotor Rating Scale for Open Field Testing in Rats” 1995,J. of Neurotrama12(1):1-21.
Ben-Bassat et al. “Processing of the Initiation Methionine from Proteins: Properties of theEscherichia coliMethionine Aminopeptidase and Its Gene Structure” 1987,J. Bacteriol.169(2):751-757.
Bixby et al. “Neurite outgrowth on muscle cell surfaces involves extracellular matrix receptors as well as Ca2+-dependent and -independent cell adhesion molecules” 1987,Proc. Natl. Acad. Sci. USA84:2555-2559.
Blight et al. “Animal models of spinal cord injury” 2002,Top Spinal Cord Inj. Rehabi.6(2):1-13.
Bowie et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions” 1990,Science247:1306-1319.
Bradbury et al. “Chondroitinase ABC Promotes Regeneration and Functional Recovery Following Spinal Cord Injury” 2001,Soc. for Neuroscience Abstracts27(2):1835.
Bray et al., Neuronal and Nonneuronal Influences on Retinal Ganglion Cell Survival, Axonal Regrowth, and Connectivity after Axotomy, 1991,Ann. NY Acad. Sci., 214-228.
Broach et al. “Experimental Manipulation of Gene Expression” M. Inouye ed.,Academic Press, New York, pp. 83-117, 1983.
Burgess et al. “Possible Dissassociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 From its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue” 1990,J. of Cell. Bio.111:2129-2138.
Cadelli et al. “Oligodendrocyte- and Myelin-Associated Inhibitors of Neurite Outgrowth: Their Involvement in the Lack of CNS Regeneration” 1992,Exp. Neur.115:189-192.
Caggiano et al. “Chondroitinase ABCI Improves Locomotion and Bladder Function following Contusion Injury of the Rat Spinal Cord” 2005,J. Neurotrauma22(2):226-239.
Chang et al. “Extension of Neurites on Axons is Impaired by Antibodies against Specific Neural Cell Surface Glycoproteins” 1987,J. Cell. Biol.104:35

Affiliated with

Also associated with

Rating

Methods of reducing extravasation of inflammatory cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of reducing extravasation of inflammatory cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing extravasation of inflammatory cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2716836